SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Alprazolam XR Tablets
Trade Name: XANAX XR; XANOR SR; TAFIL SR
Synonyms: Alprazolam Extended Release Tablets
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antianxiety agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification
Reproductive Toxicity: Category 2 Effects on or via lactation

EU Classification:
EU Indication of danger: Toxic to reproduction, Category 2

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R64 - May cause harm to breast-fed babies.

Label Elements

Signal Word: Warning
Hazard Statements:
H361d - Suspected of damaging the unborn child
H362 - May cause harm to breast-fed children

Precautionary Statements:
P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
SAFETY DATA SHEET

Material Name: Alprazolam XR Tablets
Revision date: 07-Jul-2014
Page 2 of 9
Version: 2.0

Other Hazards
Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprazolam</td>
<td>28981-97-7</td>
<td>249-349-2</td>
<td>Xn;R22</td>
<td>Acute Tox.4 (H302)</td>
<td>0.1-0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat.2;R61</td>
<td>Repr.2 (H361d)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>R64</td>
<td>Lact.(H362)</td>
<td></td>
</tr>
<tr>
<td>Silicon dioxide, NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures
Eye Contact:
Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact:
Wash exposed area with soap and water, remove contaminated clothing and obtain medical assistance if irritation occurs.
Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: No data available
Medical Conditions Aggravated by Exposure: None known

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: May include oxides of carbon.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Use appropriate ventilation. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

Specific end use(s): Pharmaceutical drug product
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Alprazolam
Pfizer OEL TWA-8 Hr: 3 µg/m³

Silicon dioxide, NF
Australia TWA: 2 mg/m³
Austria OEL - MAKs: 4 mg/m³
   0.3 mg/m³
Czech Republic OEL - TWA: 0.1 mg/m³
   4.0 mg/m³
Estonia OEL - TWA: 2 mg/m³
Finland OEL - TWA: 5 mg/m³
Germany - TRGS 900 - TWAs: 4 mg/m³
   Germany (DFG) - MAK: 4 mg/m³
Ireland OEL - TWAs: 6 mg/m³
   2.4 mg/m³
Latvia OEL - TWA: 1 mg/m³
OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf
   Listed
Slovakia OEL - TWA: 4.0 mg/m³
Switzerland OEL -TWAs: 4 mg/m³
   0.3 mg/m³

Magnesium stearate
ACGIH Threshold Limit Value (TWA): 10 mg/m³
Lithuania OEL - TWA: 5 mg/m³
Sweden OEL - TWAs: 5 mg/m³

Exposure Controls

Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:
Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:
Wear safety glasses or goggles if eye contact is possible.

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Tablets
Color: White Yellow Blue or Green
Odor: No data available.
Odor Threshold: No data available.
Molecular Formula: Mixture
Molecular Weight: Mixture
Solvent Solubility: No data available
### 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water Solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting/Freezing Point (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition Coefficient:</td>
<td></td>
</tr>
<tr>
<td>(Method, pH, Endpoint, Value)</td>
<td>Predicted 7.4 Log D 2.50</td>
</tr>
<tr>
<td>Decomposition Temperature (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Pressure (kPa)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml)</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition Temperature (Solid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (Solids):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (Liquid) (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower Explosive Limits (Liquid) (% by Vol.):</td>
<td>No data available</td>
</tr>
<tr>
<td>Polymerization</td>
<td>Will not occur</td>
</tr>
</tbody>
</table>

### 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>No data available</td>
</tr>
<tr>
<td>Chemical Stability</td>
<td>Stable under normal conditions of use.</td>
</tr>
<tr>
<td>Possibility of Hazardous Reactions</td>
<td>No data available</td>
</tr>
<tr>
<td>Oxidizing Properties</td>
<td>No data available</td>
</tr>
<tr>
<td>Conditions to Avoid</td>
<td>Fine particles (such as dust and mists) may fuel fires/explosions.</td>
</tr>
<tr>
<td>Incompatible Materials:</td>
<td>As a precautionary measure, keep away from strong oxidizers</td>
</tr>
<tr>
<td>Hazardous Decomposition Products:</td>
<td>No data available</td>
</tr>
</tbody>
</table>

### 11. TOXICOLOGICAL INFORMATION

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information on Toxicological Effects</td>
<td>The information included in this section describes the potential hazards of the individual ingredients.</td>
</tr>
<tr>
<td>General Information:</td>
<td></td>
</tr>
<tr>
<td>Short Term:</td>
<td>Not expected to cause skin irritation. Active ingredient may be harmful if swallowed.</td>
</tr>
<tr>
<td>Long Term:</td>
<td>Animal studies indicate that this material may cause adverse effects on the nervous system, the developing fetus.</td>
</tr>
</tbody>
</table>
11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: The most common adverse effects observed with the clinical use of this drug were headache, nausea, and somnolence.

Acute Toxicity: (Species, Route, End Point, Dose)

Alprazolam
- Rat Oral LD50 1220 (F) mg/kg
- Rat Oral LD50 3100 (M) mg/kg
- Mouse Oral LD50 1410-1700 mg/kg
- Rat Intravenous LD50 ~15 mg/kg

FD&C Blue No. 2
- Rat Oral LD50 2 g/kg
- Mouse Oral LD50 2500 mg/kg

D & C yellow No. 10
- Rat Oral LD50 2000 mg/kg

Hydroxypropyl methylcellulose
- Rat Oral LD50 > 10,000 mg/kg

Magnesium stearate
- Rat Oral LD50 > 2000 mg/kg
- Rat Inhalation LC50 > 2000 mg/m³

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Alprazolam
- Eye Irritation Rabbit Mild
- Skin Irritation Rabbit Non-irritating

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Alprazolam
- 1 Year(s) Dog Oral 3-30 mg/kg LOAEL Central nervous system
- 1 Year(s) Rat Oral 25 mg/kg/day NOAEL None identified
- 2 Year(s) Rat Oral 3, 10, 30 mg/kg/day Eyes

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Alprazolam
- Reproductive & Fertility Rat Oral 5 mg/kg/day NOAEL Negative
- Embryo / Fetal Development Rat Oral 5 mg/kg/day NOAEL Embryotoxicity
- Embryo / Fetal Development Rabbit Oral 0.5 mg/kg/day NOAEL Embryotoxicity, Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Alprazolam
- Bacterial Mutagenicity (Ames) Salmonella Negative
- In Vivo Micronucleus Rat Negative

PZ01153
11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

**Alprazolam**
- 2 Year(s) Rat Oral 30 mg/kg/day Not carcinogenic
- 104 Week(s) Mouse Oral 10 mg/kg/day Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Partition Coefficient: (Method, pH, Endpoint, Value)

**Alprazolam**
- Predicted 7.4 Log D 2.50

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.
15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 1, Subdivision A

Alprazolam
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: developmental toxicity initial date 7/1/90
U.S. Drug Enforcement Administration: Schedule IV Controlled Substance
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: 249-349-2

FD&C Blue No. 2
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 212-728-8

D & C yellow No. 10
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: Not Listed

Hydroxypropyl methylcellulose
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
EU EINECS/ELINCS List: Not Listed

Silicon dioxide, NF
CERCLA/SARA 313 Emission reporting: Not Listed
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
EU EINECS/ELINCS List: 231-545-4
15. REGULATORY INFORMATION

Magnesium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Not Listed
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

Lactose
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 200-559-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children

Toxic to Reproduction: Category 3
Xn - Harmful
R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

Data Sources:
- Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:
- Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity.

Revision date: 07-Jul-2014
Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet